AzTrials
AzTrials

HIV InfectionsPhase 1NCT03220724

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

A Phase 1 study testing CH505TF, CH505w53 and CH505w78 in people with HIV Infections, run by National Institute of Allergy and Infectious Diseases (NIAID) at 8 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
HIV Infections
What is being tested?
CH505TF, CH505w53 and CH505w78
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
117 participants
Where
8 sitesUnited States
Study dates
22 Aug 2017to 21 Mar 2023
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • General and Demographic Criteria:
  • Age of 18 through 50 years
  • Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willingness to be followed for the planned duration of the study
  • Ability and willingness to provide informed consent
  • Assessment of understanding: volunteer demonstrates understanding of this study, completes a questionnaire prior to first vaccination with verbal demonstration of understanding of all questionnaire items answered incorrectly
  • Agrees not to enroll in another study of an investigational research agent before the last required protocol clinic visit
Show all 43Show fewer
  • Willing to be contacted by phone, text message, or e-mail 6 months after completion of the scheduled clinic visits
  • Good general health as shown by medical history, physical exam, and screening laboratory tests
  • HIV-Related Criteria:
  • Willingness to receive HIV test results
  • Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling.
  • Assessed by the clinic staff as being at "low risk" for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit.
  • Laboratory Inclusion Values:
  • Hemogram/Complete Blood Count (CBC):
  • Hemoglobin greater than or equal to 11.5 g/dL for volunteers who were born female, greater than or equal to 13.0 g/dL for volunteers who were born male
  • White blood cell count equal to 3,300 to 12,000 cells/mm^3
  • Total lymphocyte count greater than or equal to 800 cells/mm^3
  • Remaining differential either within institutional normal range or with site physician approval
  • Platelets equal to 125,000 to 550,000/mm^3
  • Chemistry:
  • Chemistry panel: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase less than 1.25 times the institutional upper limit of normal; creatinine less than or equal to institutional upper limit of normal.
  • Virology:
  • Negative HIV-1 and -2 blood test: Volunteers must have a negative Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA).
  • Negative Hepatitis B surface antigen (HBsAg)
  • Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive
  • Urine:
  • Normal urine:
  • Negative urine glucose, and
  • Negative or trace urine protein, and
  • Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic urinalysis with red blood cells levels within institutional normal range).
  • Reproductive Status:
  • Volunteers who were born female: negative serum or urine beta human chorionic gonadotropin (beta-HCG) pregnancy test performed prior to vaccination on the day of initial vaccination. Persons who are NOT of reproductive potential due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing.
  • Reproductive status: A volunteer who was born female must:
  • Agree to consistently use effective contraception (see the protocol for more information) for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit. Effective contraception is defined as using the following methods:
  • Condoms (male or female) with or without a spermicide,
  • Diaphragm or cervical cap with spermicide,
  • Intrauterine device (IUD),
  • Hormonal contraception, or
  • Any other contraceptive method approved by the HVTN 115 Protocol Safety Review Team (PSRT)
  • Successful vasectomy in the male partner (considered successful if a volunteer reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy);
  • Or not be of reproductive potential, such as having reached menopause (no menses for 1 year) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation;
  • Or be sexually abstinent.
  • Volunteers who were born female must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit

Who cannot join

  • General:
  • Blood products received within 120 days before first vaccination
  • Investigational research agents received within 30 days before first vaccination
  • Body mass index (BMI) greater than or equal to 40; or BMI greater than or equal to 35 with 2 or more of the following: age greater than 45, systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, known hyperlipidemia
  • Intent to participate in another study of an investigational research agent or any other study that requires non-HVTN HIV antibody testing during the planned duration of the HVTN 115 study
  • Pregnant or breastfeeding
Show all 50Show fewer
  • Active duty and reserve U.S. military personnel
  • Vaccines and Other Injections:
  • HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 115 PSRT will determine eligibility on a case-by-case basis.
  • Previous receipt of monoclonal antibodies (mAbs), whether licensed or investigational; the HVTN 115 PSRT will determine eligibility on a case-by-case basis.
  • Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine trial. Exceptions may be made for vaccines that have subsequently undergone licensure by the FDA or by the national regulatory authority where the volunteer is enrolling. For volunteers who have received control/placebo in an experimental vaccine trial, the HVTN 115 PSRT will determine eligibility on a case-by-case basis. For volunteers who have received an experimental vaccine(s) greater than 5 years ago, eligibility for enrollment will be determined by the HVTN 115 PSRT on a case-by-case basis.
  • Live attenuated vaccines received within 30 days before first vaccination or scheduled within 14 days after injection (e.g., measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever; live attenuated influenza vaccine)
  • Any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (e.g., tetanus, pneumococcal, Hepatitis A or B)
  • Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled within 14 days after first vaccination
  • Immune System:
  • Immunosuppressive medications received within 168 days before first vaccination. (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral prednisone or equivalent at doses less than 60 mg/kg/day and length of therapy less than 11 days with completion at least 30 days prior to enrollment.)
  • Serious adverse reactions to vaccines or to vaccine components including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a volunteer who had a nonanaphylactic adverse reaction to pertussis vaccine as a child.)
  • Immunoglobulin received within 60 days before first vaccination
  • Autoimmune disease, current or history
  • Adverse events of special interest (AESIs)
  • Volunteers who currently have, or have a history of, any condition that could be considered an AESI for the products administered in this protocol (representative examples are listed in the study protocol)
  • Immunodeficiency
  • Clinically Significant Medical Conditions:
  • Untreated or incompletely treated syphilis infection
  • Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
  • A process that would affect the immune response,
  • A process that would require medication that affects the immune response,
  • Any contraindication to repeated injections or blood draws,
  • A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period,
  • A condition or process for which signs or symptoms could be confused with reactions to vaccine, or
  • Any condition specifically listed among the exclusion criteria below.
  • Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a volunteer's ability to give informed consent
  • Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
  • Current anti-tuberculosis (TB) prophylaxis or therapy
  • Asthma exclusion criteria: Asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report). Exclude a volunteer who:
  • Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or
  • Uses moderate/high dose inhaled corticosteroids, or
  • In the past year has either of the following:
  • Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids;
  • Needed emergency care, urgent care, hospitalization, or intubation for asthma.
  • Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes.)
  • Thyroidectomy, or thyroid disease requiring medication during the last 12 months
  • Hypertension:
  • If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well-controlled blood pressure is defined as consistently less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg diastolic. For these volunteers, blood pressure must be less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.
  • If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure greater than or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or equal to 100 mm Hg at enrollment.
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
  • Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
  • Seizure disorder: History of seizure(s) within past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
  • Asplenia: any condition resulting in the absence of a functional spleen
  • History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

United States8 sites

  • Alabama CRS

    Birmingham, Alabama, 35294

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

    Boston, Massachusetts, 02115-6110

  • Columbia P&S CRS

    New York, New York, 10032-3732

  • New York Blood Center CRS

    New York, New York, 10065

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104

  • University of Rochester Vaccines to Prevent HIV Infection CRS

    Rochester, New York, 14642

  • Bridge HIV CRS

    San Francisco, California, 94102

  • Seattle Vaccine and Prevention CRS

    Seattle, Washington, 98104

Other trials in United States

About this study

Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adult Participants

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults.

Read the detailed description

This study will evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults. The three individual EnvSeq-1 HIV vaccine Envs used in this study are called CH505TF gp120, CH505w53 gp120, and CH505w78 gp120.

This study will take place in two parts: Part A and Part B. Participants in Part A will be randomly assigned to one of four groups. Participants in each group will receive CH505TF (admixed with GLA-SE) or placebo by intramuscular (IM) injection at Months 0, 2, 4, 8, and 12.

Study researchers will evaluate participant data from Part A of the study prior to enrolling participants into Part B of the study. Researchers will also evaluate data from Part A to determine the dosing for Part B.

Participants in Part B will be randomly assigned to one of four groups. Participants in each group will receive IM injections at Months 0, 2, 4, 8. GLA-SE will be admixed with all the CH505 gp120 vaccines. Part B, Group 5 will follow a sequential approach to EnvSeq-1 vaccine administration with administration of the CH505TF vaccine at Month 0, then CH505w53 at Month 2, and CH505w78 at Months 4, and 8. Part B, Group 6 participants will follow an additive approach to EnvSeq-1 administration with administration of the CH505TF vaccine at Month 0; then the CH505TF and CH505w53 vaccines at Month 2; then the CH505TF, CH505w53 and CH505w78 vaccines at Month 4; then the CH505w53 and CH505w78 vaccines at Month 8. Part B, Group 7 participants will receive CH505 M5 at Months 0, 2, 4, and 8. Part B, Group 8 participants will receive placebo injections at each time point.

Additional study visits will occur through Month 18 for participants in Part A and through Month 14 for participants in Part B. Visits may include physical examinations and clinical assessments; blood, urine, and stool collection; HIV testing; risk reduction counseling; and interviews/questionnaires. Study staff will contact participants for follow-up health monitoring at Month 24 for participants in Part A and at Month 20 for participants in Part B.

Part C will be an open-label study arm using the EnvSeq-1 proteins in sequential administration (CH505TF, CH505w53, and CH505w78 gp120s) at the same dose as in Part B (400 mcg) to allow for in-depth analysis of B cell precursor frequency.

Conditions
HIV Infections
Being tested
CH505TF, CH505w53, CH505w78, CH505 M5, GLA-SE adjuvant
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CH505TFBiological

    Also called CH505TF gp120

    Administered by intramuscular (IM) injection in the thigh

  • CH505w53Biological

    Also called CH505w53 gp120

    Administered by IM injection in the thigh

  • CH505w78Biological

    Also called CH505w78 gp120

    Administered by IM injection in the thigh

  • CH505 M5Biological

    Also called CH505 M5 gp120

    Administered by IM injection in the thigh

  • GLA-SE adjuvantBiological

    Admixed with all CH505 gp120 proteins

  • PlaceboBiological

    Administered by IM injection in the thigh

Study groups in NCT03220724
Study groupRoleWhat they receive
Part A: Group 1ExperimentalParticipants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
Receives: Biological: CH505TF; Biological: GLA-SE adjuvant
Part A: Group 2ExperimentalParticipants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
Receives: Biological: CH505TF; Biological: GLA-SE adjuvant
Part A: Group 3ExperimentalParticipants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
Receives: Biological: CH505TF; Biological: GLA-SE adjuvant
Part A: Group 4Placebo comparatorParticipants will receive placebo at Months 0, 2, 4, 8, and 12.
Receives: Biological: Placebo
Part B: Group 5ExperimentalParticipants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, and 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
Receives: Biological: CH505TF; Biological: CH505w53; Biological: CH505w78; Biological: GLA-SE adjuvant
Part B: Group 6ExperimentalParticipants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
Receives: Biological: CH505TF; Biological: CH505w53; Biological: CH505w78; Biological: GLA-SE adjuvant
Part B: Group 7ExperimentalParticipants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, and 8.
Receives: Biological: CH505 M5; Biological: GLA-SE adjuvant
Part B: Group 8Placebo comparatorParticipants will receive placebo at Months 0, 2, 4, and 8.
Receives: Biological: Placebo
Part C: Group 9ExperimentalParticipants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4.
Receives: Biological: CH505TF; Biological: CH505w53; Biological: CH505w78

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regime

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4, 8, 12

  2. Part A: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms During the Vaccine Regime

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4, 8, 12

  3. Part A: Number of Participants With Early Study Termination Associated With an Adverse Event (AE) or Reactogenicity During the Vaccine Regime

    From the study termination form, early termination reasons associated with an AE or reactogenicity are tabulated by treatment arm

    Measured: Measured through Month 24

  4. Part A: Number of Participants With Study Product Discontinuation Associated With an AE or Reactogenicity

    From the study product discontinuation form, study product administration reasons are tabulated by treatment arm

    Measured: Measured through the Month 12 boost

  5. Part A: Chemistry and Hematology Laboratory Measures, for Each Boost: Alkaline Phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) in U/L

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, 12, and at Month 15

  6. Part A: Chemistry and Hematology Laboratory Measures, for Each Boost: Hemoglobin, Creatinine in g/dL

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, 12, and at Month 15

  7. Part A: Chemistry and Hematology Laboratory Measures, for Each Boost: White Blood Cell (WBC), Platelets, Lymphocytes, Neutrophils

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, 12, and at Month 15

  8. Part A: Occurrence of HIV-specific Immunoglobulin G (IgG) Responses 2 Weeks After the Third Vaccination With CH505TF gp120

    Serum HIV-1-specific IgG responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  9. Part A: Level of HIV-specific IgG Responses 2 Weeks After the Third Vaccination With CH505TF gp120

    Serum HIV-1-specific IgG responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  10. Part A: Occurrence of HIV-specific Immunoglobulin A (IgA) Responses 2 Weeks After the Third Vaccination With CH505TF gp120

    Serum HIV-1-specific IgA responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  11. Part A: Level of HIV-specific IgA Responses 2 Weeks After the Third Vaccination With CH505TF gp120

    Serum HIV-1-specific IgA responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  12. Number of Part B Participants Reporting Local Reactogenicity Signs and Symptoms

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4, 8

  13. Number of Part B Participants Reporting Systemic Reactogenicity Signs and Symptoms

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4, 8

  14. Part B: Number of Participants With Early Study Termination Associated With an AE or Reactogenicity During the Vaccine Regime

    From the study termination form, early termination reasons associated with an AE or reactogenicity are tabulated by treatment arm

    Measured: Measured through Month 20

  15. Number of Part B Participants With Study Product Discontinuation Associated With an AE or Reactogenicity

    From the study product discontinuation form, study product administration reasons are tabulated by treatment arm

    Measured: Measured through the Month 8 boost

  16. Part B Chemistry and Hematology Laboratory Measures, for Each Boost: Alkaline Phosphatase, AST, ALT in U/L

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, and at Month 11

  17. Part B Chemistry and Hematology Laboratory Measures, for Each Boost: Hemoglobin, Creatinine in g/dL

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, and at Month 11

  18. Part B Chemistry and Hematology Laboratory Measures

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, 8, and at Month 11

  19. Part B Magnitude and Breadth of Neutralizing Antibody Response Against Autologous Viral Isolates and Related CH103 and CH235 Precursor Detection Isolates 2 Weeks After the Fourth Vaccinations

    Magnitude-breadth characterize the magnitude (ID50) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the proportion of isolates among the virus panel with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) integrates magnitude and breadth information and provides effective tools to display, summarize, and compare multi-viral immunological data in the context of HIV-1 vaccine trials.

    Measured: Measured at Month 8.5

  20. Part B Magnitude and Breadth of Neutralizing Antibody Responses Against a Panel of Heterologous Tier 2 Isolates Induced 2 Weeks After the Fourth Vaccinations

    Magnitude-breadth characterize the magnitude (ID50) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the proportion of isolates among the virus panel with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) integrates magnitude and breadth information and provides effective tools to display, summarize, and compare multi-viral immunological data in the context of HIV-1 vaccine trials.

    Measured: Measured at Month 8.5

  21. Number of Part C Participants Reporting Local Reactogenicity Signs and Symptoms

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4

  22. Number of Part C Participants Reporting Systemic Reactogenicity Signs and Symptoms

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 [July 2017], The maximum grade observed for each symptom over the time frame is presented.

    Measured: Measured through Month Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4

  23. Part C: Number of Participants With Early Study Termination Associated With an AE or Reactogenicity During the Vaccine Regime

    From the study termination form, early termination reasons associated with an AE or reactogenicity are tabulated by treatment arm

    Measured: Measured through Month 16

  24. Number of Part C Participants With Study Product Discontinuation Associated With an AE or Reactogenicity

    From the study product discontinuation form, study product administration reasons are tabulated by treatment arm

    Measured: Measured through the Month 4 administration

  25. Part C Chemistry and Hematology Laboratory Measures, for Each Boost: Alkaline Phosphatase, AST, ALT in U/L

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, and at Month 10

  26. Part C Chemistry and Hematology Laboratory Measures, for Each Boost: Hemoglobin, Creatinine in g/dL

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, and at Month 10

  27. Part C Chemistry and Hematology Laboratory Measures

    Laboratory results are summarized by analyte and timepoint. Analytes and timepoint combinations with no grade 1 or higher results are not shown.

    Measured: Measured during screening, and 2 weeks after each vaccination at Month 0, 2, 4, and at Month 10

Secondary outcomes (23)

  1. Part C Magnitude and Breadth of Neutralizing Antibody Response Against Autologous Viral Isolates and Related CH103 and CH235 Precursor Detection Isolates 2 Weeks After the Third (Final) Vaccination

    Magnitude-breadth characterize the magnitude (ID50) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the proportion of isolates among the virus panel with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) integrates magnitude and breadth information and provides effective tools to display, summarize, and compare multi-viral immunological data in the context of HIV-1 vaccine trials. Six autologous isolates were assayed and included for the AUC-MB calculation: CH0505.w4.3, CH0505.w53.16, CH0505.w78.e33, CH0505.w100.B6, CH0505s, and CH0505TF.M5.

    Measured: Measured at Month 4.5

  2. Part C Magnitude and Breadth of Neutralizing Antibody Responses Against a Panel of Heterologous Tier 2 Isolates Induced 2 Weeks After the Third (Final) Vaccination

    Magnitude-breadth characterize the magnitude (ID50) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the proportion of isolates among the virus panel with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) integrates magnitude and breadth information and provides effective tools to display, summarize, and compare multi-viral immunological data in the context of HIV-1 vaccine trials. Six autologous isolates were assayed and included for the AUC-MB calculation: CH0505.w4.3, CH0505.w53.16, CH0505.w78.e33, CH0505.w100.B6, CH0505s, and CH0505TF.M5.

    Measured: Measured at Month 4.5

  3. Part A: Occurence of Memory B Cells Differentially Binding to the CH505 Wildtype gp120 TF Env vs the Mutant CH505 Env I Delta 371 gp120 2 Weeks After the Third Vaccination With CH505TF gp120

    The CD4 binding-site (CD4bs) and Env-specific B cells were quantified using biotinylated CH505TF gp120 protein probes and the CD4bs-mutant in the context of a flow cytometry panel to identify and characterize those B cells. Post-vaccine samples are defined as positive responders if the frequency of Env-specific B cells for the post-vaccine data was statistically greater than that for the data from baseline, compared by one-sided Fisher's exact test. The Fisher's exact test is not applied to compare between endpoints.

    Measured: Measured at Month 4.5

  4. Part A: Level of Memory B Cells Differentially Binding to the CH505 Wildtype gp120 TF Env vs the Mutant CH505 Env I Delta 371 gp120 2 Weeks After the Third Vaccination With CH505TF gp120

    The CD4 binding-site (CD4bs) and Env-specific B cells were quantified using biotinylated CH505TF gp120 protein probes and the CD4bs-mutant in the context of a flow cytometry panel to identify and characterize those B cells. The reported frequencies are: The % CH505+ of total B cells equals the frequency of double-positive CH505 gp120+ B cells out of total B cells; the % CD4bs CH505+ of total B cells equals the frequency of double-positive CH505 gp120+ B cells that are negative for the CD4bs mutant (CH505 I delta 371) out of total B cells; the % CH505+ of IgG+ B cells equals the frequency of double-positive CH505 gp120+ IgG+ B cells out of IgG+ B cells; and the % CD4bs CH505+ of IgG+ B cells equals the frequency of double-positive CH505 gp120+ IgG+ B cells that are negative for the CD4bs mutant (CH505 I delta 371) out of IgG+ B cells.

    Measured: Measured at Month 4.5

  5. Part A: Magnitude and Breadth of Neutralizing Antibody Responses Against Autologous Viral Isolates as Assessed by Area Under the Magnitude-breadth Curves 2 Weeks After the Third Vaccination With CH505TF gp120

    Magnitude-breadth characterize the magnitude (ID50) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the proportion of isolates among the virus panel with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) integrates magnitude and breadth information and provides effective tools to display, summarize, and compare multi-viral immunological data in the context of HIV-1 vaccine trials. Six autologous isolates were assayed and included for the AUC-MB calculation: CH0505.w4.3, CH0505.w53.16, CH0505.w78.e33, CH0505.w100.B6, CH0505s, and CH0505TF.M5.

    Measured: Measured at Month 4.5

  6. Part A: Occurrence of CD4+ T-cell Responses as Assessed by Intracellular Cytokine Staining Assays (ICS) 2 Weeks After the Third and Fifth Vaccination With CH505TF

    PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. Response positivity is derived by testing if the number of cells expressing the marker is equal in the stimulated vs. unstimulated cells. Response is positive if the one-sided Fisher's exact test (discrete Bonferroni adjustment over the peptide pools) p greater than or equal to 0.00001. The Fisher's exact test is not applied to compare between endpoints. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.

    Measured: Measured at Months 4.5 and 12.5

  7. Part A: Level of CD4+ T-cell Responses as Assessed by Intracellular Cytokine Staining Assays (ICS) 2 Weeks After the Third and Fifth Vaccination With CH505TF

    PBMC samples are stimulated with synthetic peptide pools or left unstimulated as a negative control. For each sample, T-cell subset, and peptide pool, response magnitude is % cells expressing markers after peptide stimulation minus % cells expressing markers after no stimulation. Response positivity is derived by testing if the number of cells expressing the marker is equal in the stimulated vs. unstimulated cells. Response is positive if the one-sided Fisher's exact test (discrete Bonferroni adjustment over the peptide pools) p greater than or equal to 0.00001. The Fisher's exact test is not applied to compare between endpoints. Data are excluded if the blood draw date was outside the visit window, the participant was HIV-infected, PBMC viability or T-cell count were low, or negative control was high.

    Measured: Measured at Months 4.5 and 12.5

  8. Part A: Occurrence of Monoclonal Antibodies Evaluated for CD4 Binding Site Loop Binding

    ELISA responses were measured at serial three-fold serum dilutions from 1:30 to 1:(30×3^11 = 5,314,410) for each analyte. Positive responses are defined as (analyte optical density (OD)) > 3×(background OD) in wells of dilutions 1:30 and 1:90.

    Measured: Measured at Month 4.5

  9. Part A: Level of Monoclonal Antibodies Evaluated for CD4 Binding Site Loop Binding

    ELISA responses were measured at serial three-fold serum dilutions from 1:30 to 1:(30×3^11 = 5,314,410) for each analyte. The area under the dilution-magnitude curve (AUC) was calculated as the average untransformed optical density (OD) over the log10 dilutions using the trapezoidal rule.

    Measured: Measured at Month 4.5

  10. Part B: Occurrence of HIV-specific Binding Antibody (Ab) Responses as Assessed by Binding Ab Multiplex Assay 2 Weeks After the Second and After the Fourth Vaccinations

    Serum HIV-1-specific immunoglobulin G (IgG) responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 2.5 and 8.5

  11. Part B: Level of HIV-specific Binding Ab Responses as Assessed by Binding Ab Multiplex Assay 2 Weeks After the Second and After the Fourth Vaccinations

    Serum HIV-1-specific IgG responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 2.5 and 8.5

  12. Part B: Occurrence of CD4+ T-cell Responses as Assessed by Intracellular Cytokine Staining (ICS) Assays 2 Weeks After the Second and Fourth (Final) Vaccinations With EnvSeq-1 Immunogens or CH505 M5 gp120

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  13. Part B: Level of CD4+ T-cell Responses as Assessed by Intracellular Cytokine Staining (ICS) Assays 2 Weeks After the Second and Fourth (Final) Vaccinations With EnvSeq-1 Immunogens or CH505 M5 gp120

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  14. Part B: Occurrence of Monoclonal Antibodies Evaluated for CD4 Binding Site Loop Binding

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  15. Part B: Level of Monoclonal Antibodies Evaluated for CD4 Binding Site Loop Binding

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  16. Part C: Percent B Cells Expressing Candidate CH103 Precursors With Immunogenetics, Function, and Structure Similar to CH103 Lineage Antibodies

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  17. Part C: Alterations in Frequency of CH103-like Precursor B Cells Prior to CH505 TF (First) Vaccination and After the Final Vaccination

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  18. Part C: Characterization of B-cell Derived Antibodies (Binding, Neutralization and Structure Compared With the CH103 Lineage Members, Including the UCA)

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  19. Part C: Occurrence of HIV-specific IgG Responses as Assessed by Binding Ab Multiplex Assay 2 Weeks After the Final Vaccination

    Serum HIV-1-specific IgG responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  20. Part C: Level of HIV-specific Binding Ab Responses as Assessed by Binding Ab Multiplex Assay 2 Weeks After the Final Vaccination

    Serum HIV-1-specific IgG responses were measured on a Bio-Plex instrument using a standardized custom Luminex assay. The readout is background-subtracted mean fluorescent intensity (MFI), with background adjustment for an antigen-specific plate level control. For each sample, response magnitude is net MFI, defined as experimental antigen MFI minus reference antigen MFI. Net MFI less than 1 is set to 1. The measure unit fluorescence units are relative to assay background, not relative to the placebo arm. Background is used here rather than negative control stimulation, since the antigens are used as bead coating rather than stimulation.

    Measured: Measured at Month 4.5

  21. Part C: Frequencies, Specificity and Phenotype of Vaccine-induced B-cell Responses as Measured by Multiparameter Flow Cytometry After Each Vaccination Compared to Baseline

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  22. Part C: Characterization of the B-cell Derived Antibodies (Binding of CH505 TF, wk53, wk78 Proteins), Neutralization of Autologous or Mutant CH505 Viruses, and Structure

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

  23. Part C: Response Rate and Magnitude of CD4+ T-cell Responses as Assessed by ICS Assays 2 Weeks After the Final Vaccination

    No data are available. The protocol-specified assays required to generate these data were not performed due to insufficient remaining funds at the end of the study, unrelated to participant safety or study conduct issues. Prespecified measurement values were not obtained and they will not be collected in the future.

    Measured: No data

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2017
  2. Study start22 Aug 2017
  3. Primary completion21 Mar 2023
  4. Study completion21 Mar 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
117 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03220724
Sponsor's protocol ID
HVTN 115
Other IDs
12042
Status last verified
Feb 2026
First submitted
12 Jul 2017
Last updated
4 May 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Wolfe LS, Smedley JG 3rd, Bubna N, Hussain A, Harper R, Mostafa S. Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates. Vaccine. 2021 Jun 29;39(29):3852-3861. doi: 10.1016/j.vaccine.2021.05.073. Epub 2021 Jun 4.

    PubMed 34099325

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing CH505TF, CH505w53 and CH505w78 in people with HIV Infections, run by National Institute of Allergy and Infectious Diseases (NIAID) at 8 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 43 inclusion and 50 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Feb 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regime (time frame: Measured through Month Measured through 7 days after the vaccination at Month 0, 2, 4, 8, 12). The study lists 27 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03220724, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in